86 related articles for article (PubMed ID: 1093667)
1. Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer.
Coune A; Smith P
Cancer Chemother Rep; 1975; 59(1):209-13. PubMed ID: 1093667
[TBL] [Abstract][Full Text] [Related]
2. [Bromocriptine, a new therapeutic principle in prostatic adenoma and carcinoma. Basis, possibilities, limits].
Jacobi GH; Altwein JE
Dtsch Med Wochenschr; 1978 May; 103(19):827-33. PubMed ID: 77217
[No Abstract] [Full Text] [Related]
3. Effect of bromo-ergocryptine on serum hPRL, hLH, hFSH, and estradiol 17-beta in women with galactorrhea-amenorrhea.
Dickey RP; Stone SC
Obstet Gynecol; 1976 Jul; 48(1):84-9. PubMed ID: 934580
[TBL] [Abstract][Full Text] [Related]
4. Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154).
Martin-Comin J; Pujol-Amat P; Cararach V; Davi E; Robyn C
Obstet Gynecol; 1976 Dec; 48(6):703-6. PubMed ID: 1036613
[TBL] [Abstract][Full Text] [Related]
5. The effect of bromocriptine in patients with benign prostatic hypertrophy.
Farrar DJ; Pryor JS
Br J Urol; 1976 Feb; 48(1):73-5. PubMed ID: 57815
[TBL] [Abstract][Full Text] [Related]
6. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
Stracke H; Heinlein W; Horowski R; Schatz H
Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Horti J; Figg WD; Weinberger B; Kohler D; Sartor O
Oncol Rep; 1998; 5(4):893-6. PubMed ID: 9625840
[TBL] [Abstract][Full Text] [Related]
8. [The "problem" of stopping loctation prevention and suppression with CB 154 (author's transl)].
Schneider D
Schweiz Rundsch Med Prax; 1976 Jan; 65(2):54-6. PubMed ID: 1257199
[No Abstract] [Full Text] [Related]
9. Infertility due to hyperprolactinemia and its treatment with ergocryptine.
Canales ES; Forsbach G; Soria J; Zárate A
Fertil Steril; 1976 Nov; 27(11):1335-6. PubMed ID: 989750
[No Abstract] [Full Text] [Related]
10. [Value of palliative treatment of metastasizing prostatic cancer with the prolactin inhibitor parlodel].
Ausfeld R; Huber P; Del Pozo E
Helv Chir Acta; 1982 Aug; 49(3-4):459-62. PubMed ID: 6182128
[No Abstract] [Full Text] [Related]
11. [Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].
Agnoli A; Casacchia M; Carolei A; Meco G; Zamponi A; Ruggieri S
Minerva Med; 1976 Nov; 67(53):. PubMed ID: 1036612
[TBL] [Abstract][Full Text] [Related]
12. The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.
Jeromin L
Int Urol Nephrol; 1982; 14(1):51-6. PubMed ID: 6889585
[TBL] [Abstract][Full Text] [Related]
13. [Clinical experience with bromocriptine, a central dopaminergic stimulator].
Ludin HP; Kunz F; Lörincz P; Ringwald E
Nervenarzt; 1976 Nov; 47(11):651-5. PubMed ID: 794749
[No Abstract] [Full Text] [Related]
14. Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study.
Aydin Y; Atis A; Kaleli S; Uludağ S; Goker N
Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):203-6. PubMed ID: 20206430
[TBL] [Abstract][Full Text] [Related]
15. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
17. [Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline].
Mussa A; Sandrucci S; Dogliotti L
Minerva Med; 1979 Nov; 70(51):3493-8. PubMed ID: 522987
[TBL] [Abstract][Full Text] [Related]
18. [Bromocriptine for palliation of advanced prostatic carcinoma. Experimental and clinical profile of a drug (author's' transl)].
Jacobi GH; Altwein JE
Urol Int; 1979; 34(4):266-90. PubMed ID: 89747
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate.
Müntzing J; Shukla SK; Chu TM; Mittelman A; Murphy GP
Invest Urol; 1974 Jul; 12(1):65-8. PubMed ID: 4835492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
